Page 58 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 58
Chapter 3
88% (78-94) 78% (69-84) 78% (67-86) Predictive Negative (95% CI) Value
20% (11-32) 35% (22-50) 62% (47-75) Predictive a Positive Value (95% CI) 56% (46-66) 75% (66-82) 79% (69-87) Specificity (95% CI) Diagnostic information at 2 years 59% (36-78) 38% (25-54) 60% (46-74) Sensitivity (95% CI)
90% (85-93) 80% (72-86) 76% (65-85) 80% (71-88) 91% (83-95)
42% (33-51) 60% (49-69) 59% (46-70) 42% (30-54) 74% (51-88)
74% (68-79) 72% (63-79) 68% (57-77) 63% (54-72) 94% (87-97)
70% (58-79) 70% (59-79) 68% (54-79) 63% (48-76) 64% (43-80)
82% (67-91) 85% (73-92) 85% (72-92) 85% (79-89)
50% (25-75) 55% (34-74) 23% (14-35) 33% (22-47)
84% (69-92) 83% (71-91) 49% (39-59) 85% (80-89)
46% (23-71) 58% (36-77) 64% (43-80) 33% (20-46)
91% (78-97)
26% (15-43)
56% (43-68)
75% (46-91)
86% (75-92)
37% (25-51)
63% (52-72)
68% (49-82)
89% (79-94) 86% (75-92) NR
50% (35-64) 28% (14-47) NR
75% (64-83) 75% (64-84) NR
72% (54-85) 44% (23-67) NR
HR 95% CI Prognostic information univariate
3·89 1·07 - 14·22 5·26 1·90 - 14·58 1·45 0·71 - 2·97 5·31 3·29 - 8·56 2·70 0·68 - 10·67 2·85 1·38 – 5·87 2·45 1·01 - 5·93 cc cc 1·9 1·1 - 3·2 ee bb bb NR NR 54 (18·4%)
12 (24·0%)
20 (27·4%)
51 (44·7%)
60 (53·6%)
34 (49·3%)
25 (28·4%)
14 (31·1%)
117(35·8%)
Safar et al (2012) PFS living: 38 (4·4 -73) 42 (37·5%) 4·77 2·26 - 10·05 39 d d d 35 (75% at least
Fan et al (2017) PFS 26 (2-75) 42 (35·3%) 4·46 2·42-8·23 Kim et al (2017) PFS 31 (8-75) 43 (28·7%) 1·81 0·95-3·45 Kong et al (2016) PFS 32 (9-59) 19 (18·1%) 9·74 3·27 - 28·99 Mikhaeel et al (2016) PFS 45·6 (15·6- 94·8) 65 (44·2%) 2·18 1·11 - 4·27 Mamot et al (2015) EFS 45 (4-64) 58 (46·4%) 3·23 1·78 - 5·89 Zhang et al (2015) PFS 30 (5-94) 87 (44·2%) 2·74 1·52 - 4·93 28·8 (5·8-52·6)
relapse: 6 (1-32)
living: 39 (12-74)
death: 17 (3-55)
Surviving: 46·8
29 (3.3-86)
36 (0·8-84)
26·2 (8-67)
29 (2-80)
De Oliveira Costa et al PFS 41·5 (0·6- 71·1) 51 (45·9%) NR NR 24 mo)
27 (7-73)
(2·4- 78)
38 cc 40 cc 42
43
45
49
37 cc 34 bb 35 bb 41 bb 44 ff 48
50 dd 47 dd Dabaja et al (2014) PFS
Mylam et al (2014) PFS
Gonzalez-Barca et al EFS
Carr et al (2014) EFS
Nols et al (2014) PFS
Fuertes et al (2013) PFS
Pregno et al (2012) PFS
Lanic et al (2012) PFS
Itti et al (2013) PFS
36
46
(2016)
(2013)
positive no (%) Interim PET
Median follow-up in months (range)
Table 3 Study results; prognostic and diagnostic information
Results Outcome measure
56
First author, year
